QUARTERLY UPDATE | News for Donors, Sponsors, Patients, Doctors, and Hospitals • The Jed Ian Taxel Foundation for Rare Cancer Research 
Why is it called rare cancer if it's not rare?
Over 200,000 patients are diagnosed with a rare cancer each year in the U.S. alone, and this diagnosis is usually a death sentence. A recent British Journal of Cancer article, "Rare Cancers: The Greatest Inequality in Cancer Research and Oncology Treatment," states that rare cancers comprise a staggering 198 varieties. When looking at the main expenditure in cancer research by leading research funding agencies, however, the question is: where does funding go? The amount of funding is generally related to the single most prevalent forms of cancer and rarely includes significant funding for rare cancer research.
Founder's Forum 
by Mark Taxel

Jed never wanted to be
defined by his cancer.
Jed never wanted to be defined by his cancer. To the degree possible, he diligently maintained his normal routines: sharing coffee with me (or Tiff or Linda) first thing in the morning; regular emails and phone calls with friends; a couple hours of pool and sun time in the afternoon; after-breakfast walks with Linda; a TV movie nightly with Tiff; family dinners…
Jed had many unfulfilled dreams that ranged from starting new businesses, creating and curating his art, designing unique spaces at our farm like a dinner/ summer movie space in one of the barns, or an event space, and so, so much more.  

This foundation is now his legacy. A legacy that contributes to the betterment of mankind. That is a legacy he would want…one not defined by cancer but defined by the outcome. The foundation is the vehicle … accelerating scientific discovery…science that translates into breakthrough treatments and maybe even cures for rare cancers. Science and its applications that result in More Healthy Survivors. 

An outcome, a legacy worthy of a young life with unfulfilled dreams…cut way too short. 
Get Ready for Cycle for Survival 2022
We're teaming up to raise funds for rare cancer research.
Cycle for Survival is an annual
fundraiser to end rare cancers.
Launched in 2007 by Jennifer Goodman Linn, a sarcoma patient and Equinox club member, Cycle for Survival stationary-cycling rides and virtual events have raised $289 million dollars for rare cancer research and lifesaving clinical trials at Memorial Sloan Kettering Cancer Center (MSK), a world leader in cancer research, care, and education.

You have what it takes to help us
raise hundreds of thousands of dollars this spring!
We ride to honor Jed. WE'RE ALL JEDIS FOR SURVIVAL. Join one of our JEDIs for Survival regional teams – visit our website to meet our JEDI Captains and fundraise – 100% of every donation goes directly to lifesaving rare cancer research.

Our foundation is matching the first
$10,000 raised by each of our regional teams.
That's right, we'll double your fundraising impact. $160,000 for rare cancer research at MSK is our GOAL.
Why I Ride: Alex Wolin
Jed Ian Taxel Foundation Board Member, NYC JEDI Team Captain, and National Team Lead
“My cousin Jed Taxel lost his battle with rare cancer in 2017 and I ride for him. I first learned about Cycle for Survival while taking a spin class at Equinox in 2018. I thought ‘Wow, what a great cause’ and assembled a team at work. I quickly discovered that most people had someone in their lives who had been touched by rare cancer. The teams we created raised over $30,000!

My Uncle Mark was our biggest supporter and when The Jed Ian Taxel Foundation for Rare Cancer Research was created he said, ‘Why don’t we form a National Cycle Team that represents our foundation and taps into the power and scale of the Cycle for Survival program? The foundation can multiply funds by matching dollars raised by the team.’ I’m now a JIT Foundation board member and our National Cycling Team Lead. It’s my 3rd year riding to end rare cancers and I’m excited to see the impact we’re going to make. That's why I ride."
Rare Cancers: Great Unmet Medical Needs
Columbia University CME Conference April 26, 2022
The Jed Ian Taxel Foundation for Rare Cancer Research
Conference Cosponsor
Rare Cancers: Great Unmet Medical Needs is a one-day symposium in NYC sponsored by our foundation and Columbia University Herbert Irving Comprehensive Cancer Center that brings together leading cancer experts to discuss advances in rare cancer research, propose future directions in cancer medicine for rare cancers, and delineate a blueprint for investing resources in the treatment and cure of rare cancers. The conference is organized and led by Dr. Gary Schwartz, Professor of Medicine at CUMC, Columbia University Vagelos College of Physicians and Surgeons.

Rare Cancers: Great Unmet Medical Needs
Columbia University, NYC, NY
April 26, 2022 • 8:30am – 5:50pm EST  
CME accredited and designated for a maximum of 8 AMA credits
Cosponsored by Jed Ian Taxel Foundation and Columbia University Herbert Irving Comprehensive Cancer Center
You did it!
We raised over $400,000 in 2021, exceeding our goal by $150,000
A night to remember
$400,00 raised in 2021
Love never dies
How did the foundation accomplish so much in such a short period of time?

• Credit our defining a clear mission, with clear
and present need.

• Credit our active volunteer Board of Directors
with their diverse skills and capabilities who
all leaned into making our first year exceed all its goals.

• Credit our ability to build strong relationships
with donors, medical centers and leaders,
patients and families, government, and much
more to come…

A night to remember...
On October 24, 2021, we hosted our first Friends and Family Dinner Fundraiser at Il Cantinori in Manhattan. We came together to memorialize Jed and officially launch The Jed Ian Taxel Foundation and its mission: funding innovative rare cancer research and accelerating discovery of treatments that can save lives. Our heartfelt thanks to more than 200 very generous donors including our 90 dinner attendees. We couldn’t have accomplished this fundraiser without our incredible donors, foundation board members and volunteers, our sponsors Casamigos Tequila and Positive Promotions, and staff at Il Cantinori.
Partnering with Columbia University Comprehensive Cancer Center
Its Leaders Spoke at Our Fundraiser
Dr. Jordan S. Orange, PhD, Reuben S. Carpentier Professor and Chair Department of Pediatrics, Vagelos College of Physicians and Surgeons Columbia University Physician In-Chief, Morgan Stanley Children’s Hospital New-York Presbyterian, shared these inspiring words:
“I am inspired to see the strength and power of the people in this room. I’ve had the privilege of meeting an extraordinary community and this is the group that can make the difference."
Dr. Anil K. Rustgi, Director of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center (CUMC) welcomed The Jed Ian Taxel Foundation to the Columbia University family and invited foundation president Mark Taxel to join the Columbia Memorial Hospital Patient and Family Advisory Council.
Dr. Michael Weiner, Vice Chair and Hettiger Professor of Columbia Children's Health at CUMC has joined The Jed Ian Taxel Foundation Board of Directors and initiated the foundation's co-sponsorship with Columbia University of a one-day conference that will bring together rare cancer experts from all over the country.
Your Voice Matters
Comment, Like, Share & Follow Us on Social Media.
Together, we can take action against rare cancers and help save lives.
The Jed Ian Taxel Foundation for Rare Cancer Research, Inc. is a 501(c)(3) Nonprofit Organization, accepting Tax Deductible Donations from individuals, corporations, family-advised funds, and foundations. Federal Tax ID 86-261081